Tuesday, November 10, 2015

Nimesulide tablet for pain killer

Nimesuilde is a pain killer NSAIDs drug is the best prescribed drug for treatment of acute pain, Primary dysmennorhea and also to treat degenerative joint disease.
Nimesulide drug was launched in Italy for the first time as Aulin and Mesulid in 1985 and is presentlyavailable in more than 50 countries worldwide with different trademarks.
Its multifactorial mode of action gives it a unique and broad action on inflammatory processes.
It has superior gastrointestinal safety as compared to other NSAIDs. It is an analgesic and antipyretic in action, other than its anti inflammatory action. 
Unlike, other NSAIDs, the chemical structure of nimesulide does not contain a carboxylic group but a sulfonanilide moiety as the acidic group. 
Apart from tablet the drug- Nimesulide is also available in various forms such as in the form of Gell, powder, and suppositories. It’s also available in various brand names of Sulide, Nimalox, Nimesil, Nimulid, Nicip, Nimcap, Nise, Sulidene and Zolan e.t.c.The Nimulid Transgel a brand from Nimesulide Transdermal Gel is indicated for post-traumatic inflammation, acute musculoskeletal disorders including sprains, strains, tendinitis, tenosynovitis, low back pain, periarthritis (shoulder pain) and osteoarthritis (joint pains), stiffness.
As with all drugs, therapy appropriateness when using nimesulide is of outmost importance to safeguard patient’s health and guarantee the product’s therapeutic value.
NImesulide is available in the dosage of 100 mgs for tablets, 100 mg for granules for oral suspension, 200mg for suppositories and 3% of gel. And the prescribed duration to use is for 15 days. 
Continuous use of NImesulide may cause cetain side effects like Diarrhea, vomiting, skin rash e.t.c, It also preffered to use for the age above 12. Women should use the drug with caution during lactation and it is contraindicated during pregnancy.
It must be used under supervision by a doctor in accordance with the approved indications and in compliance with the recommendations 

No comments:

Post a Comment